Minesse (Ethinylestradiol, Gestodene | Lactose Anhydrous)

The two hormones act together to block the mid‑cycle luteinising hormone surge, which stops ovulation. Ethinylestradiol stabilises the endometrial lining, while Gestodene thickens cervical mucus and further reduces endometrial growth, creating multiple barriers that prevent fertilisation and implantation.

The dosing regimen for Minesse is determined by the prescribing clinician. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and duration are individualized based on patient needs and medical guidance.

Minesse is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant health.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Minesse. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minesse contains Ethinylestradiol and Gestodene, a progestogen with a relatively low androgenic profile, which may result in fewer acne‑related side effects compared with some older formulations. Its efficacy in preventing pregnancy is comparable to other approved combined pills, while the safety profile aligns with class‑wide expectations.

Minesse tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children. Do not use tablets that appear discoloured or damaged.

Minesse is taken orally, usually once daily, preferably at the same time each day. The tablet should be swallowed whole with water and not chewed or broken. Consistency in timing helps maintain stable hormone levels and maximises contraceptive effectiveness.

Serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to stroke or myocardial infarction, severe hypertension, hepatic adenoma, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe headache, or visual changes.

Minesse is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known hypersensitivity to any component, or who smoke heavily (more than 15 cigarettes per day) and are over 35 years of age. A thorough medical assessment is required before initiating therapy.